ORBi: Legrand Victor - Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.

Reference : Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le pati...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Cardiovascular & respiratory systems Human health sciences : Endocrinology, metabolism & nutrition
	To cite this reference:	http://hdl.handle.net/2268/23759

Title :	Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
Language :	French
Alternative title :	[en] Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches
Author, co-author :	Legrand, Victor [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
	Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
	Nyssen, Astrid [ > > ]
Publication date :	2009
Journal title :	Revue Médicale de Liège
Publisher :	Hopital de Baviere
Volume :	64
Issue/season :	4
Pages :	192-8
ISSN :	0370-629X
City :	Liège
Country :	Belgique
Keywords :	[en] Angioplasty, Transluminal, Percutaneous Coronary/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/therapeutic use ; Belgium/epidemiology ; Cardiovascular Agents/therapeutic use ; Coronary Restenosis/epidemiology/prevention & control ; Coronary Thrombosis/therapy ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 2/complications ; Drug Therapy, Combination ; Evidence-Based Medicine ; Fatty Acids, Omega-3/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Immunologic Factors/therapeutic use ; Incidence ; Meta-Analysis as Topic ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Stents
Abstract :	[en] Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Target :	Researchers ; Professionals ; Students
Permalink :	http://hdl.handle.net/2268/23759
Other URL :	http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	200904_05.pdf		Publisher postprint	383.75 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5